中晚期食管癌患者放疗前血清TGF-β1、TSP1、SCCA水平与放疗效果的相关性研究
Correlation between Serum TGF-β1,TSP1,SCCA Levels and Radiothera-peutic Effect in Patients with Advanced Esophageal Cancer before Radio-therapy
易成凤 1陈小英 1胡湘尘 1彭蓉 1解发鹏2
作者信息
- 1. 615000 四川西昌,凉山彝族自治州第二人民医院核医学科
- 2. 615099 四川西昌,凉山彝族自治州第一人民医院核医学科
- 折叠
摘要
目的 分析中晚期食管癌患者放疗前血清转化生长因子-β1(TGF-β1)、血小板反应蛋白1(TSP1)、鳞状细胞癌抗原(SCCA)水平与放疗效果的相关性,以利于临床治疗方案的制订、防止延误治疗.方法 回顾分析2019 年6 月至2023 年6 月收治的109 例中晚期食管癌放疗患者的临床资料,根据放疗效果分为无效组21 例和有效组88 例.比较2 组患者临床资料,应用二元Logistic回归模型分析中晚期食管癌患者放疗效果的影响因素,绘制受试者工作特征(ROC)曲线分析放疗前TGF-β1、TSP1、SCCA对中晚期食管癌患者放疗效果的预测价值.结果 无效组临床分期Ⅳ期、放疗剂量≤60 Gy的患者比例高于有效组(P＜0.05).2 组放疗后血清TGF-β1、SCCA水平均较放疗前降低,TSP1 水平均较放疗前升高(P＜0.05);有效组放疗前后血清TGF-β1、SCCA水平均低于无效组,TSP1 水平均高于无效组(P＜0.05,P＜0.01).二元Logistic回归分析显示:临床分期及放疗前血清TGF-β1、TSP1、SCCA水平均为中晚期食管癌患者放疗效果的危险因素(P＜0.01).ROC曲线分析显示,放疗前血清TGF-β1、TSP1、SCCA水平及三者联合预测中晚期食管癌患者放疗效果的预测价值均较好.随访 12 个月,有效组生存率为 89.77%(79/88)高于无效组的66.67%(14/21),差异有统计学意义(P＜0.01).结论 中晚期食管癌患者放疗效果与临床分期及放疗前血清TGF-β1、TSP1、SCCA水平存在密切联系,临床可通过检测放疗前血清TGF-β1、TSP1、SCCA水平预测中晚期食管癌患者放疗效果,有助于指导临床治疗方案的制订,从而防止延误治疗,提高患者生存率.
Abstract
Objective To analyze the correlation between the levels of serum transforming growth factor-β1(TGF-β1),thrombospondin-1(TSP1),squamous cell carcinoma antigen(SCCA)and radiotherapeutic effect in patients with advanced esophageal cancer before radiotherapy,so as to facilitate the formulation of clinical treatment plans and prevent de-layed treatment.Methods The clinical data of 109 patients with advanced esophageal cancer treated with radiotherapy from June 2019 to June 2023 were retrospectively analyzed and divided into an ineffective group(n=21)and an effective group(n=88)according to the radiotherapeutic effect.The clinical data of the two groups were compared,and the factors influen-cing the radiotherapeutic effect of patients with advanced esophageal cancer were analyzed by binary Logistic regression model.The predictive value of TGF-β1,TSP1 and SCCA before radiotherapy was analyzed by drawing receiver operating characteristic(ROC)curve.Results The proportion of patients with clinical stageⅣand radiotherapy dose≤60 Gy in the ineffective group was higher than that in the effective group(P＜0.05).The serum levels of TGF-β1 and SCCA in the two groups after radiother-apy were lower than those before radiotherapy,while the levels of TSP1 were higher than those before radiotherapy(P＜0.05).Serum TGF-β1 and SCCA levels in the effective group were lower than those in the ineffective group before and after radiothera-py,while TSP1 levels were higher than those in the ineffective group(P＜0.05,P＜0.01).Binary Logistic regression analysis showed that clinical stage and serum TGF-β1,TSP1 and SCCA levels before radiotherapy were all risk factors for radiotherapeu-tic effect in patients with advanced esophageal cancer(P＜0.01).ROC curve analysis showed that serum TGF-β1,TSP1 and SCCA levels alone and in combination before radiotherapy were effective in predicting the radiotherapeutic effect of patients with advanced esophageal cancer.At 12-month follow-up,the survival rate of the effective group was 89.77%(79/88),which was higher than that of the ineffective group[66.67%(14/21)],showing significant differences(P＜0.01).Conclusion There is a close relationship of radiotherapeutic effect with clinical stage and serum levels of TGF-β1,TSP1 and SCCA in patients with advanced esophageal cancer before radiotherapy.In clinical practice,it is possible to predict radiotherapeutic effect of patients with advanced esophageal cancer by detecting serum levels of TGF-β1,TSP1 and SCCA before radiotherapy,which can help guide the formulation of clinical treatment plans,prevent delayed treatment,and improve survival rates of patients.
关键词
食管肿瘤/转化生长因子-β1/血小板反应蛋白1/鳞状细胞癌抗原/放疗/影响因素分析/预测效能Key words
Esophageal tumor/Transforming growth factor-β1/Thrombospondin 1/Squamous cell carcinoma anti-gen/Radiotherapy/Analysis of influencing factors/Predictive efficacy引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据